381 related articles for article (PubMed ID: 28249598)
1. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
Lundon DJ; Boland A; Prencipe M; Hurley G; O'Neill A; Kay E; Aherne ST; Doolan P; Madden SF; Clynes M; Morrissey C; Fitzpatrick JM; Watson RW
BMC Cancer; 2017 Mar; 17(1):163. PubMed ID: 28249598
[TBL] [Abstract][Full Text] [Related]
2. Identification of transcription factors associated with castration-resistance: is the serum responsive factor a potential therapeutic target?
Prencipe M; Madden SF; O'Neill A; O'Hurley G; Culhane A; O'Connor D; Klocker H; Kay EW; Gallagher WM; Watson WR
Prostate; 2013 May; 73(7):743-53. PubMed ID: 23359479
[TBL] [Abstract][Full Text] [Related]
3. The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases.
O'Hurley G; Prencipe M; Lundon D; O'Neill A; Boyce S; O'Grady A; Gallagher WM; Morrissey C; Kay EW; Watson RW
Prostate; 2014 Feb; 74(3):306-13. PubMed ID: 24249383
[TBL] [Abstract][Full Text] [Related]
4. Relationship between serum response factor and androgen receptor in prostate cancer.
Prencipe M; O'Neill A; O'Hurley G; Nguyen LK; Fabre A; Bjartell A; Gallagher WM; Morrissey C; Kay EW; Watson RW
Prostate; 2015 Nov; 75(15):1704-17. PubMed ID: 26250344
[TBL] [Abstract][Full Text] [Related]
5. Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance.
Zhang M; Osisami M; Dai J; Keller JM; Escara-Wilke J; Mizokami A; Keller ET
Mol Cancer Res; 2017 Apr; 15(4):457-466. PubMed ID: 28087740
[TBL] [Abstract][Full Text] [Related]
6. Identification of docetaxel resistance genes in castration-resistant prostate cancer.
Marín-Aguilera M; Codony-Servat J; Kalko SG; Fernández PL; Bermudo R; Buxo E; Ribal MJ; Gascón P; Mellado B
Mol Cancer Ther; 2012 Feb; 11(2):329-39. PubMed ID: 22027694
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
Marín-Aguilera M; Codony-Servat J; Reig Ò; Lozano JJ; Fernández PL; Pereira MV; Jiménez N; Donovan M; Puig P; Mengual L; Bermudo R; Font A; Gallardo E; Ribal MJ; Alcaraz A; Gascón P; Mellado B
Mol Cancer Ther; 2014 May; 13(5):1270-84. PubMed ID: 24659820
[TBL] [Abstract][Full Text] [Related]
8. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
[TBL] [Abstract][Full Text] [Related]
9. Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.
Codony-Servat J; Marín-Aguilera M; Visa L; García-Albéniz X; Pineda E; Fernández PL; Filella X; Gascón P; Mellado B
Prostate; 2013 Apr; 73(5):512-21. PubMed ID: 23038213
[TBL] [Abstract][Full Text] [Related]
10. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
[TBL] [Abstract][Full Text] [Related]
11. Combination of Nexrutine and docetaxel suppresses NFκB-mediated activation of c-FLIP.
Zhang Y; Li L; Wang J; Cheng W; Zhang J; Li X; Zhang Z; Gong J; Ghosh R; Kumar AP; Xie J
Mol Carcinog; 2017 Oct; 56(10):2200-2209. PubMed ID: 28485511
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel.
Desarnaud F; Geck P; Parkin C; Carpinito G; Makarovskiy AN
Cancer Biol Ther; 2011 Jan; 11(2):204-12. PubMed ID: 21057205
[TBL] [Abstract][Full Text] [Related]
13. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.
O'Neill AJ; Prencipe M; Dowling C; Fan Y; Mulrane L; Gallagher WM; O'Connor D; O'Connor R; Devery A; Corcoran C; Rani S; O'Driscoll L; Fitzpatrick JM; Watson RW
Mol Cancer; 2011 Oct; 10():126. PubMed ID: 21982118
[TBL] [Abstract][Full Text] [Related]
14. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer.
Li Y; Kucuk O; Hussain M; Abrams J; Cher ML; Sarkar FH
Cancer Res; 2006 May; 66(9):4816-25. PubMed ID: 16651437
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
17. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
18. The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines.
O'Connell K; Prencipe M; O'Neill A; Corcoran C; Rani S; Henry M; Dowling P; Meleady P; O'Driscoll L; Watson W; O'Connor R
Proteomics; 2012 Jul; 12(13):2115-26. PubMed ID: 22623417
[TBL] [Abstract][Full Text] [Related]
19. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer.
Garrido MF; Martin NJ; Bertrand M; Gaudin C; Commo F; El Kalaany N; Al Nakouzi N; Fazli L; Del Nery E; Camonis J; Perez F; Lerondel S; Le Pape A; Compagno D; Gleave M; Loriot Y; Désaubry L; Vagner S; Fizazi K; Chauchereau A
Clin Cancer Res; 2019 Jan; 25(2):710-723. PubMed ID: 30322877
[TBL] [Abstract][Full Text] [Related]
20. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]